Filter my results
Search
Displaying 1 - 4 of 4
World Health Organization Guidelines (Option A, B, and B+) for Antiretroviral Drugs to Treat Pregnant Women and Prevent HIV Infection in Infants
By: Sierra Hope Jones, Alexis Darby
| Published: Mar 01, 2021
To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens…
HIV-positive personsHIV infectionsHIV-positive youthHIV-positive womenHIV-positive children
World Health Organization Guidelines (Option A, B, and B+) for Antiretroviral Drugs to Treat Pregnant Women and Prevent HIV Infection in Infants
By: Sierra Hope Jones, Alexis Darby
| Published: Mar 01, 2021
To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens…
HIV-positive personsHIV infectionsHIV-positive youthHIV-positive womenHIV-positive children
“Knowledge, Attitudes, and Practices of Health Personnel of Maternities in the Prevention of Mother-to-Child Transmission of HIV...” (2018), by Elie Nkwabong, Romuald Meboulou Nguel, Nelly Kamgaing, and Anne Sylvie Keddi Jippe
By: Alexis Darby, Sierra Hope Jones
| Published: Apr 06, 2021
In 2018, researchers Elie Nkwabong, Romuald Meboulou Nguel, Nelly Kamgaing, and Anne Sylvie Keddi Jippe published, “Knowledge, Attitudes, and…
LiteratureHIV-positive womenHIV-positive childrenHIV (Viruses)HIV infections
US Regulatory Response to Thalidomide (1950-2000)
By: Chanapa Tantibanchachai
| Published: Apr 01, 2014
Thalidomide, a drug capable of causing fetal abnormalities (teratogen), has caused greater than ten thousand birth defects worldwide since its…
ContextThalidomideThalidomide--Side effectsTeratogenicity testingMultiple Myeloma